Clinical trialNCT05997017RecruitingPhase 2Interventional

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

SponsorAadi Bioscience, Inc.Enrollment29CancerEndometrial CancerEndometrioid Endometrial CancerEndometrioid TumorRecurrent Endometrial CarcinomaTumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Willis Navarro, MD
Aadi Bioscience
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Michael Birrer, Md, Phd
Little Rock, Arkansas, United States
Recruiting
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Brian Slomovitz, MD
Recruiting
Women'S Cancer Center of Nevada
Las Vegas, Nevada, United States
Nicola M Spirtos, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Angela Green, MD
Recruiting
Levine Cancer Institute
Charlotte, North Carolina, United States
Allison M Puechi, MD
Recruiting
Oklahoma University Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Lauren Dockery, MD
Recruiting
Women & Infants Hospital
Providence, Rhode Island, United States
Cara Mathews, MD
Recruiting
Texas Oncology - Tyler
Tyler, Texas, United States
Anna Priebe, MD
Recruiting
Swedish Cancer Institute
Seattle, Washington, United States
Fernanda Musa, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Nab-sirolimus

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Dec 2023
Primary completion: 31 Dec 2026
Completion: 30 Jun 2027
Last update posted: 13 Nov 2025
Registered enrollment: 29
Registry id: NCT05997017

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.